Spondyloarthritis & psoriatic arthritis
Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis
Authors' conclusion
Applying N-of-1 trials and Bayesian analysis effectively optimized NSAID therapy for axSpA in terms of efficacy and accounting for side effect profile.
Study context
- Population
- Patients meeting ASAS criteria for axial spondyloarthritis (axSpA)30 completed
- Participants
- 42 patients
- Comparison
- Celecoxib vs meloxicam vs naproxen, each for 4 weeks
- Primary endpoint
- Change in ASDAS
Methodological detailsdouble-blind, crossover, two cycles, Bayesian analysis
- Double-blind
- Crossover
- Two cycles
- Bayesian analysis
Primary result
As reported in the abstract
All three NSAIDs reduced Ankylosing Spondylitis Disease Activity Score (ASDAS) overall across all individuals (PPB of >0 reduction)
>0.99
Further findings
| Outcome | Preferred NSAID | Least effective NSAID |
|---|---|---|
| ASDAS reduction, preferred NSAID vs least effective NSAID (per patient) | 0.88 | 0.12 |
- ASDAS reduction, preferred NSAID vs least effective NSAID (per patient) — PPB of larger reduction
- >0.99
- ASDAS reduction, preferred NSAID vs least effective NSAID (per patient) — PPB of potential clinically important improvement (PPB [0.6])
- 0.96
Patient preference
- Patient preferences varied, with individualized responses identified through Bayesian analysis
Original publication
Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis. Rheumatology (Oxford). Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →